Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells
- PMID: 8279947
- DOI: 10.1007/BF01379102
Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells
Abstract
Fifteen vaccinia virus (VV) recombinants derived from VV strains Praha, LIVP and DD (i.e. Dryvax Wyeth vaccine-derived) and expressing genes for S, preS2-S or c antigens of hepatitis B virus (HBV) were tested in monkey CV-1 cells and human diploid LEP cells. The production of infectious virus was found to be alike in all the recombinants and parental viruses as well. However, several recombinants produced markedly lesser amounts of S and preS2 antigens in LEP cells than in CV-1 cells. This reduction was independent of the parental virus used. There was, however, a relationship between the production of preS2 in CV-1 cells and the production of S and preS2 antigens in LEP cells; in general, recombinants efficiently inducing preS2 antigen formation in CV-1 cells produced markedly reduced amounts of S and preS2 antigens in LEP cells. Reduction of HBV antigen production in LEP cells was not apparent in recombinants expressing only S or c antigens of HBV, and the production of c antigen by double recombinants was not influenced by simultaneous expression of preS2 and S. The various recombinants also differed in the ratio of S:preS2 antigen formation. This difference seemed to be associated with the length of the untranslated leader sequence preceding preS2 but not with the parental virus or cell type used. The titers of antibodies against S and preS2 antigens induced in mice immunized with different recombinants differed markedly. The differences in the ratio of S:preS2 antigen production in vitro were not reflected in vivo by S:preS2 antibody ratio.
Similar articles
-
Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.Acta Virol. 1996 Nov-Dec;40(5-6):273-9. Acta Virol. 1996. PMID: 9171455
-
Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I.Vaccine. 1996 Aug;14(11):1045-52. doi: 10.1016/0264-410x(96)00008-4. Vaccine. 1996. PMID: 8879101
-
Synthesis and immunogenicity of hepatitis B virus envelope antigen expressed by recombinant vaccinia virus. Finding of retention signal in the C-terminal portion of the preS1 domain of subtype adyw.Arch Virol. 1991;121(1-4):29-41. doi: 10.1007/BF01316742. Arch Virol. 1991. PMID: 1759909
-
A recombinant vaccinia virus expressing hepatitis B virus middle surface protein. Restricted expression of HBV antigens in human diploid cells.Arch Virol. 1990;112(3-4):181-93. doi: 10.1007/BF01323163. Arch Virol. 1990. PMID: 2378567
-
Applications of human hepatitis B virus preS domain in bio- and nanotechnology.World J Gastroenterol. 2015 Jun 28;21(24):7400-11. doi: 10.3748/wjg.v21.i24.7400. World J Gastroenterol. 2015. PMID: 26139986 Free PMC article. Review.
Cited by
-
Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.Cancer Gene Ther. 2014 Mar;21(3):115-25. doi: 10.1038/cgt.2014.6. Epub 2014 Feb 21. Cancer Gene Ther. 2014. PMID: 24556712
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous